HARTMANN closes 2025 financial year with higher sales and earnings

Heidenheim, 19 March 2026. HARTMANN continued to develop successfully in a challenging market environment in the 2025 financial year and strengthened its competitive position. The Company was particularly affected by cuts and uncertainties in product reimbursements in key market segments but was nevertheless able to increase sales and adjusted EBITDA once again despite these difficult conditions.

The HARTMANN GROUP generated sales revenues of EUR 2,449.6 million in 2025. This corresponds to organic sales growth of 2.2% compared to the previous year. Market share was gained in strategic core segments, particularly through new product launches.

Adjusted EBITDA was EUR 276.9 million, up EUR 15.5 million on the previous year. The EBITDA margin increased by 0.4 percentage points to 11.3% compared to 2024. The implementation of growth and cost measures from the Transformation Program contributed over EUR 50 million to the renewed improvement in earnings in 2025. Advance spending on sales and marketing for the launch of new products and the impact of US tariff policy had a dampening effect on earnings in the financial year. Material and energy costs also remained at a high level.

Significant structural changes and projects were implemented in 2025. These included the successful migration of the SAP system to S/4 HANA on time and within budget.

The Wound Care segment generated sales of EUR 623.6 million (organic sales growth: 2.6%). The advanced wound care business continued to drive growth in 2025, primarily through atraumatic dressings based on Zetuvit® Silicone and Resposorb® Silicone. Significant market share gains were achieved in the outpatient care sector, particularly in the US. In contrast, business in Germany and France was impacted by changes and reductions in reimbursements.

The Incontinence Management segment generated sales of EUR 785.8 million (organic sales growth: 2.8%) and recorded solid organic growth in all product categories. The incontinence pants business benefited from successful product relaunches and the introduction of absorbent underwear.

The Infection Management segment recorded sales of EUR 537.6 million (organic sales growth: 3.3%). Product innovations in surface disinfection led to strong growth in this business and significant market share gains. New products for orthopedic surgery also had a very positive impact.

Sales revenues in the Complementary Group Divisions segment amounted to EUR 502.6 million (organic sales development: -0.2%). While Kneipp and the KOB Group recorded sales growth, the CMC Group saw a decline due to portfolio optimizations.

HARTMANN is adhering to its long-standing principle of a dividend policy based on continuity and proposing a dividend of EUR 8 per share.

Britta Fünfstück, CEO of the HARTMANN GROUP: “Following the transformation phase from 2019 to 2025, all core segments are on a solid footing. The divisions are gaining market share in important areas thanks to a significantly increased rate of innovation combined with a competitive cost position. In the coming years, the PLUS₂₀₃₀ strategy developed in 2025 will build on this solid foundation. Our goal is to continue to achieve stronger growth in terms of market share and margins compared to the competition.”

HARTMANN expects the positive development to continue in the 2026 financial year in a market and competitive environment that remains challenging. The Company anticipates moderate organic sales growth and adjusted EBITDA in the range of EUR 270 to 310 million.

In addition to its 2025 Annual Report, HARTMANN has also published its 2025 Sustainability Report. For the first time, this report is based on the requirements of the Corporate Sustainability Reporting Directive (CSRD) and the associated European Sustainability Reporting Standards (ESRS). It reports on the targets set in connection with climate protection and adaptation to climate change, as well as CO2 emissions in 2025, which were reduced by 11% (Scope 1+2*) compared to the previous year. In addition, the Company has significantly increased the share of renewable energy used from 18% in 2024 to 23% in 2025.

* Scope 1: direct emissions from sources within the company; Scope 2: indirect emissions from the consumption of purchased energy

The annual report and financial statements for the 2025 financial year can be found in German at https://corporate.hartmann.info/de-de/investor-relations

The 2025 Sustainability Report can be found at https://corporate.hartmann.info/en/who-we-are/sustainability

The HARTMANN GROUP is one of the leading European providers of professional medical and care products and associated services. Every day, healthcare professionals and patients rely on HARTMANN brands in the segments of Incontinence Management (e.g. MoliCare®), Wound Care (e.g. Zetuvit®, Cosmopor®) and Infection Management (e.g. Sterillium®). This is expressed in our brand promise of “Helps. Cares. Protects.” Founded in 1818, the Company sells its products and solutions in 130 countries around the world.

To learn more about the HARTMANN GROUP, visit www.corporate.hartmann.info.